Neurocrine Biosciences reported $2.85 in EPS Earnings Per Share for its fiscal quarter ending in June of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2025 2.05 2.17 Nov/03
FY2026Q2 Jun/2026 2.85 1.58 1.65 Jul/30
FY2026Q1 Mar/2026 1.94 1.15 0.70 May/05
FY2025Q4 Dec/2025 1.88 1.86 1.69 Feb/11
FY2025Q3 Sep/2025 2.17 1.56 1.81 Oct/28




Eps Change Date
AbbVie USD 3.65 1 Jun/2026
Acadia Pharmaceuticals USD 0.18 0.16 Jun/2026
Agios Pharmaceuticals USD -1.69 0 Jun/2026
ALKERMES USD 0 0.4 Jun/2026
Alnylam Pharmaceuticals USD 1.84 0.15 Jun/2026
Amgen USD 6.29 1.14 Jun/2026
Biogen USD 3.6 0.03 Jun/2026
BioMarin Pharmaceutical USD 0.76 0.3 Mar/2026
Cytokinetics USD -1.67 0.17 Mar/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Exelixis USD 0.91 0.04 Jun/2026
Gilead Sciences USD -6.75 8.78 Jun/2026
Halozyme Therapeutics USD 1.6 1.84 Mar/2026
Incyte USD 3.09 1.28 Jun/2026
Ionis Pharmaceuticals USD -0.69 0.13 Jun/2026
Nektar Therapeutics USD -1.78 0.43 Mar/2026
Neurocrine Biosciences USD 2.85 0.91 Jun/2026
Pfizer USD 0.77 0.02 Jun/2026
Prothena USD 0.6 1.06 Mar/2026
Regeneron Pharmaceuticals USD 14.29 4.82 Jun/2026
Repligen USD 0.54 0.06 Jun/2026
Rigel Pharmaceuticals USD 0.7 0.76 Sep/2024
Sarepta Therapeutics USD 0.64 2.52 Jun/2026
Teva Pharmaceutical Industries USD 0.06 1.51 Jun/2026
Ultragenyx Pharmaceutical USD -0.9 0.94 Jun/2026
Vertex Pharmaceuticals USD 4.73 0.26 Jun/2026